Evofem Biosciences, Inc. Enters into Exclusive Distributorship Agreement for Sub-Saharan Africa

Evofem Biosciences, Inc. has entered into a five-year exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC. for the commercialization of SOLOSEC® (secnidazole) 2 g oral granules in Sub-Saharan Africa. The agreement, effective April 24, 2026, designates Clovis Davis Pharmaceuticals as the lead distributor responsible for marketing, sales, and promotion of SOLOSEC® within the specified territory. Regulatory filings for SOLOSEC® in the territory will be based on the U.S. FDA approval. Evofem announced this partnership on April 27, 2026. The agreement details various terms including definitions, appointment, term, intellectual property, confidentiality, parties' obligations, product defects, liability, termination clauses, and dispute resolution. Both parties will adhere to specific legal and regulatory requirements within the territory. The agreement also outlines procedures for product delivery, insurance, and potential recalls, emphasizing the distributor's responsibility for local marketing and sales efforts while Evofem provides promotional materials and product supply.